According to filings with the U.S. Securities and Exchange Commission, Morphic is raising $100,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Praveen Tipirneni played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Morphic
Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohns disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs, until now.

To learn more about Morphic, visit http://morphictx.com/

Contact:
Praveen Tipirneni, Chief Executive Officer
781-996-0955
https://www.linkedin.com/in/praveen-tipirneni-42a1a5/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.